Ironwood Pharmaceuticals, Inc. (IRWD) Guidance & Earnings Results
On 2026-08-06 Ironwood Pharmaceuticals, Inc. raised guidance: "LINZESS net sales guidance raised to $1.15-$1.20B; total revenue $460-$485M; adjusted EBITDA…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IRWDIronwood Pharmaceuticals, Inc.Follow IRWD — free
—
Price chart with a free account
- Market cap
- 571.7M
- P/E TTM
- 4.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Raised | LINZESS net sales guidance raised to $1.15-$1.20B; total revenue $460-$485M; adjusted EBITDA >$310M · full year |
| 7 May 26 | Reaffirmed | Maintains full-year 2026 financial guidance · full year |
| 25 Feb 26 | Reaffirmed | FY2026: LINZESS U.S. net sales $1.125-1.175B; total revenues $450-475M; adjusted EBITDA >$300M · full year |
| 2 Jan 26 | Raised | LINZESS net sales $1.125-1.175B vs $860-890M; total revenue $450-475M vs $290-310M; adj EBITDA >$300M vs >$135M |
| 10 Nov 25 | Raised | LINZESS net sales guidance raised to $860-890M; total revenue $290-310M; adj EBITDA >$135M · full year |
| 7 Aug 25 | Reaffirmed | Full year 2025 financial guidance maintained; LINZESS net price in-line with expectations. · full year |
Ironwood Pharmaceuticals, Inc. — questions
- What guidance did Ironwood Pharmaceuticals, Inc. give?
- On 2026-08-06: "LINZESS net sales guidance raised to $1.15-$1.20B; total revenue $460-$485M; adjusted EBITDA >$310M"
- When does Ironwood Pharmaceuticals, Inc. report earnings?
- Ironwood Pharmaceuticals, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Ironwood Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.